Stock Events

Stock Events

Grey Matters Health 

C$0.38
0
-C$0.01-1.32% Tuesday 13:30

Statistics

Day High
0.38
Day Low
0.38
52W High
-
52W Low
-
Volume
13,000
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5MayExpected
Q1 2024
Next
-0.5
-0.17
0.17
0.5
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GREY.CN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap27.06B
Biogen focuses on neurology, a field relevant to Algernon Pharmaceuticals' interest in neurological diseases, making them direct competitors in research and development of treatments.
Lilly(Eli) &
LLY
Mkt Cap789.69B
Eli Lilly and Company has a strong portfolio in neuroscience and psychiatric medications, areas that Algernon Pharmaceuticals is also exploring, positioning them as competitors.
Pfizer
PFE
Mkt Cap153.59B
Pfizer has a broad range of pharmaceutical products, including treatments for conditions that Algernon Pharmaceuticals is targeting, making them competitors in multiple therapeutic areas.
Merck
MRK
Mkt Cap276.38B
Merck & Co., Inc. competes in the development of drugs for diseases that Algernon Pharmaceuticals is also interested in, such as neurological and respiratory diseases.
Novartis
NVS
Mkt Cap280.79B
Novartis AG has a diversified portfolio, including treatments for neurological conditions, directly competing with Algernon Pharmaceuticals' research interests.
Gilead Sciences
GILD
Mkt Cap161.85B
Gilead Sciences, Inc. is involved in the development of treatments for viral infections, an area that Algernon Pharmaceuticals has shown interest in, making them competitors.
Abbvie
ABBV
Mkt Cap351.47B
AbbVie Inc. works on neuroscience among other areas, directly competing with Algernon Pharmaceuticals in the development of treatments for neurological conditions.
AMGEN
AMGN
Mkt Cap185.74B
Amgen Inc. has a focus on innovative therapeutics, including areas that overlap with Algernon Pharmaceuticals' interests, positioning them as competitors.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap35.68B
Teva Pharmaceutical Industries Limited operates in generic and specialty medicines, including areas of interest to Algernon Pharmaceuticals, making them indirect competitors.
Johnson & Johnson
JNJ
Mkt Cap547.64B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in various therapeutic areas, including those targeted by Algernon Pharmaceuticals, making them a broad competitor.

About

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. It pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is in Phase 1 clinical trial for the treatment of strokes and traumatic brain injuries. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Show more...
CEO
ISIN
CA3978841078

Listings

F
DE
AGW2.F
CN
CA
GREY.CN
MU
DE
AGW0.MU
STU
DE
AGW0.STU

0 Comments

Share your thoughts

FAQ

What is Grey Matters Health stock price today?▼
The current price of GREY.CN is C$0.38 CAD — it has decreased by -1.32% in the past 24 hours. Watch Grey Matters Health stock price performance more closely on the chart.
What is Grey Matters Health stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Grey Matters Health stocks are traded under the ticker GREY.CN.
When is the next Grey Matters Health earnings date?▼
Grey Matters Health is going to release the next earnings report on May 05, 2026.
What were Grey Matters Health earnings last quarter?▼
GREY.CN earnings for the last quarter are -0.5 CAD per share, whereas the estimation was N/A CAD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A CAD per share.
In which sector is Grey Matters Health located?▼
Grey Matters Health operates in the Other sector.
When did Grey Matters Health complete a stock split?▼
Grey Matters Health has not had any recent stock splits.